BGI Genomics
Cong Lin is a Research Scientist at BGI Genomics since December 2017, previously serving as a Postdoctoral Researcher at Leiden University Medical Center from March 2017 to December 2017 and as a Postdoctoral Fellow at Academisch Medisch Centrum from September 2010 to December 2016. During this period, Cong Lin completed a PhD focusing on the role of coagulation factors and their receptors in idiopathic pulmonary fibrosis, culminating in a thesis entitled "Potential novel targets: Protease-Activated Receptors In Idiopathic Pulmonary Fibrosis." Prior experience includes a part-time role as a DJ and host at CRTV and an internship at The Leiden Academic Center for Drug Research. Cong Lin earned a PhD from the University of Amsterdam from 2010 to 2014 and a Master's degree in Cellular and Molecular Biology from Leiden University from 2007 to 2009.
This person is not in any offices
BGI Genomics
3 followers
BGI was founded in 1999 as a research organization to support the Human Genome Project. Over the years, BGI’s in-house research has contributed to the development of the field of Genomics in significant ways, as evidenced by a wealth of peer-reviewed publications in prestigious scientific journals. Today, BGI is actively participating in the fields of Cancer Research, Bio-sustainability and Personalized Medicine through a global network of collaborators. BGI Genomics is the world’s leading provider of genomic and proteomic services, now serving customers in more than 66 countries. We provide academic institutions, pharmaceutical companies, health care providers and other organizations with integrated genomic and proteomic services and solutions across a broad range of applications spanning basic and translational research, drug discovery, agriculture and health care. To provide these services, we operate a large network of service Laboratories in China, Hong Kong, the US and Europe. Our customers benefit from the highest level of sequencing experience in the world to support their research and drug discovery projects. Our service laboratories operate under strict internationally recognized quality systems, such as those from CAP and ISO. More recently, BGI developed and launched its own DNBseq™ sequencing technology, based on DNA Nanoball sequencing technology that was invented in our Complete Genomics research facility in Silicon Valley, California. Scientists around the world now rely on DNBseq NGS services for the highest quality data at the lowest cost.